PIPELINE
For a better future SCM Lifescience will do its best
Stem Cell Therapy
Moderate to severe atopic dermatitis
01
Disease Overview
중등증-중증 아토피 피부염

It is a chronic, recurrent inflammatory skin disease that begins in infancy or childhood.
Accompanied by pruritus, dry skin, characteristic eczema, and lichenification.

Definition
  • Atopic dermatitis is a chronic recurrent inflammatory skin disease that mainly begins in infancy or childhood, and is accompanied by pruritus (itch), dry skin, and characteristic eczema.
Cause
  • The cause of the disease is still unknown
  • Environmental factors, genetic predisposition, immunological abnormalities, and abnormal skin barrier are the main causes.
Symptom
  • Severe itching (itching), dry skin, and dermatitis (eczema) are the main symptoms
  • Dry skin causes and exacerbates itching, which is intermittent during the day and usually gets worse in the early evening or in the middle of the night.
02
Phase 2 clinical design

Primary endpoint : rate of change of EASI score at 12 weeks (EASI-50)
(Eczema Area and Severity Index , Eczema Severity Index)

  • Indication
    moderate to severe

    atopic dermatitis

  • Number of patients
    72 people

    Cohort 1: 36 subjects in the test group
    Cohort 2: 36 patients in the placebo group

  • Dosing regimen
    2 weeks intervals / 3 times

    0.5 X 106 cells/kg

  • Design
    multicenter, placebo-controlled, double-blind
clinical trial institution
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고
  • 임상시험 기관 로고